Retinal Imaging Diagnostics Patent Landscape Analysis Report 2026 Edition

Retinal Imaging Diagnostics Market Size, Growth Trends, and Industry Outlook

Retinal imaging has moved from specialist ophthalmology rooms into optometry practices, primary care clinics and community screening camps. Optical coherence tomography forms the diagnostic core for macular disease and glaucoma, while fundus photography serves high-volume diabetic retinopathy screening. Demand now favours faster scans, wider fields of view and software that grades images without a specialist reader.

Market growth is driven by the expanding population with diabetes, which raises the volume of retinal examinations needed each year. The International Diabetes Federation estimated 589 million adults living with diabetes in 2024, and clinical guidelines call for periodic retinal screening in this group. FDA clearances for autonomous screening software, supported by reimbursement under CPT code 92229, move imaging into primary care.

A 2021 meta-analysis estimated 103 million adults with diabetic retinopathy in 2020, rising to about 160 million by 2045, which signals a steady pipeline of patients who need annual imaging. A 2014 meta-analysis projected age-related macular degeneration to grow from 196 million cases in 2020 to 288 million in 2040, and every case on anti-VEGF therapy requires repeat OCT scans for retreatment decisions. These two disease curves sustain replacement and upgrade cycles for OCT and fundus platforms in clinics.

Retinal Imaging Diagnostics Patent Filing Trends and Innovation Activity

Patent filings in retinal imaging diagnostics follow the shift from standalone cameras to connected, software-driven systems. Applicants file on light sources, scanning optics, eye tracking, image reconstruction and clinical decision support, often within one family. Japanese manufacturers hold early optical and mechanical claims, while newer filers from China and the United States concentrate on algorithms.

The dataset covers more than 18,000 patent families, with filing volumes peaking between 2021 and 2023 as swept-source OCT, OCT angiography and deep learning grading reached commercial scale. Rising screening volumes and the commercial success of cleared AI systems convert directly into filings on acquisition hardware, analysis software and remote monitoring.

Scope of the Retinal Imaging Diagnostics Patent Landscape Analysis Report

The scope covers granted patents and published applications for devices, methods and software that acquire or analyse images of the retina, macula and optic nerve head. Included technologies are optical coherence tomography, fundus photography, ultra-widefield imaging, angiography, autofluorescence and adaptive optics.

Clinical applications include diabetic retinopathy, age-related macular degeneration, glaucoma, retinal vascular disease and retinopathy of prematurity. Software claims on segmentation, biomarker quantification and automated grading fall within scope, together with portable and home-use devices.

The analysis profiles imaging device manufacturers, AI software developers, university research groups and hospital systems that hold or file retinal imaging patents, and classifies assignees by portfolio size, technology focus and geographic coverage.

Global Retinal Imaging Diagnostics Patent Landscape Analysis

Retinal Imaging Diagnostics Patent Filing Trend Analysis

Annual filings for retinal imaging diagnostics are estimated to have grown at roughly 8% a year between 2020 and 2024. Growth came from artificial intelligence image analysis, OCT angiography and compact swept-source designs, which together account for the fastest-rising share of new families.

Hardware families show steady, mature filing, while software and monitoring families grow faster. Home OCT, handheld fundus cameras and smartphone-linked imagers extended the applicant base to start-ups and university spin-outs, and these entrants file mainly in the United States and China.

Leading Companies and Assignee Analysis in the Retinal Imaging Diagnostics Patent Landscape

Geographic Analysis of Retinal Imaging Diagnostics Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

China holds the largest number of retinal imaging filings, driven by domestic device makers and university groups working on deep learning grading. The United States ranks second and carries the highest density of software and remote monitoring claims. Japan follows with a deep base of optical and mechanical claims from Topcon, Canon, Nidek and Nikon.

Retinal Imaging Diagnostics Technology Segmentation and Innovation Areas

The report segments patents by technology cluster, including:

• Optical coherence tomography hardware and scanning optics
• Ultra-widefield fundus and angiography imaging
• OCT angiography and vascular quantification
• Artificial intelligence screening and grading software
• Portable, handheld and home retinal imaging

Among these, optical coherence tomography hardware and scanning optics hold the largest share of patent filings, supported by the installed base of spectral-domain and swept-source systems in retina practices.

Competitive Landscape and Emerging Trends in the Retinal Imaging Diagnostics Market

Competition centres on optical coherence tomography and fundus platforms from Carl Zeiss Meditec, Topcon, Canon, Nidek and Nikon. Each defends hardware positions with continuation filings while adding analysis software. Partnerships between camera makers and AI developers, such as the Topcon NW400 pairing with cleared screening software, link device claims to software claims.

Companies are focusing on:

• Swept-source OCT light sources and scanning speed
• Ultra-widefield optics with integrated OCT
• OCT angiography motion correction
• Deep learning for diabetic retinopathy grading
• Automated detection of macular fluid and geographic atrophy
• Home OCT and remote monitoring workflows
• Handheld and smartphone-linked fundus cameras

Emerging innovation themes include patient-operated home OCT, as shown by the 2024 De Novo authorisation of the Notal Vision Scanly Home OCT, and ultra-widefield systems that combine nine imaging modes with swept-source OCT, as in the Optos Silverstone RGB launched in October 2025. Foundation models trained on retinal images, oculomics for systemic disease detection and green autofluorescence for atrophy assessment add further filing activity.

Strategic Insights from the Retinal Imaging Diagnostics Patent Landscape

Retinal imaging diagnostics patents form a layered field. Hardware claims from Japanese and German manufacturers provide the base, software claims from the United States and China add analysis capability, and monitoring claims extend use into homes and primary care. Freedom-to-operate in OCT light sources and image analysis requires close review of continuation families.

Technology segments, assignee portfolios and jurisdictional trends in retinal imaging diagnostics are tracked across the full dataset. The report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Retinal Imaging Diagnostics Patent Landscape Analysis

The study searched patent records from the United States Patent and Trademark Office, the China National Intellectual Property Administration, the Japan Patent Office, the European Patent Office, the Korean Intellectual Property Office and the WIPO PATENTSCOPE database. Coverage runs from 2005 to 2026.

Queries combined keywords with CPC and IPC classes such as A61B 3/10, A61B 3/12, A61B 3/14, G01B 9/02091, G06T 7/00, G06V 40/18 and G16H 30/40. Records were screened for relevance, and family consolidation used priority data to group related filings.

The market side draws on regulatory databases including FDA 510(k) and De Novo records, company disclosures, clinical trial registries and peer-reviewed literature on diabetic retinopathy and macular disease epidemiology. Assignee names were normalised across subsidiaries and corporate renamings.

Related Reports

Ophthalmic Diagnostic Devices Market

Optical Coherence Tomography Market

Optical Coherence Tomography Medical Imaging Patent Landscape Report